Cipla committed to scale-up production of Lopinavir/Ritonavir (LPVr) pellets to 30,000 bottles per month in 2018 and to submitting the new “4-in-1” (ABC/3TC/LPV/r) pellets in 2018.
Cipla
Sub-Actions & Milestones
Develop 4-in-1 granules and submit to FDA in 2018
-
Granules under development. Expectation to file dossier with FDA in with BE data in Q3 and clinical data in December 2018
-
Submit the new “4-in-1” (ABC/3TC/LPV/r) pellets in 2018.
Cipla
-
-
Scale-up production of Lopinavir/Ritonavir (LPVr) pellets to 30,000 bottles per month in 2018
Cipla
-
-
Submit request to FDA for new process (change of solvent) to enable 2.5x greater production capacity
-
Request filed and approved. Moving to scale up production to 60,000/month
-
Updates
Notes
Responsible